If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
51.00    1.00 (2.00%)
Bid:
50.00
Ask:
52.00
Spread: 2.00 (4.00%)
Market Cap: £97.85m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

IOSorb Patent Awarded

2 Aug 2013 08:30

RNS Number : 8247K
Iofina PLC
02 August 2013
 



2 August 2013

 

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

 

IOSorb Patent Awarded

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to report that the Company has been awarded a US patent with regards to its IOsorb™ iodine extraction technology.

The new patent was awarded for Iofina's technology, already in use at IO#1 and IO#2, that provides removal of iodine from brine streams that contain hydrocarbon contaminates and are located at the injection site of the operator. These are key components of Iofina's technology as all the Company's sources of iodine are from hydrocarbon contaminated brine streams which are co-produced waste streams associated with shale oil and gas production based at the producer's injection site.

Conventional methods of extracting iodine are typically intolerant of high temperatures and rendered ineffective by hydrocarbon fouling. The conventional iodine extraction systems also are immobile and not modular or mobile like Iofina's WET® IOsorb™ units. This therefore makes conventional iodine extraction systems ill-suited for deployment which is also included in this patent. The issued patent was originally filed in the United States and has been also filed in Chile and Japan shortly thereafter.

Commenting, Chris Fay, Executive Chairman, said: "The IOsorb™ technology is the only technology known which is oil field proven for large scale commercial production of iodine. This patent is a key component in protecting Iofina's IOsorb™ technology utilised in the emerging shale boom in North America.

"We are delighted we have been issued the patent and will continue to finalise the Company's additional patents and trademarks relating to the Company's IOsorb™ technology to ensure a robust intellectual property (IP) portfolio for the Company."

 

 

For further information, please contact:

 

Dr. Chris Fay, Executive Chairman

Iofina plc

Tel: +44(0)20 3006 3135

www.iofina.com

 

Ben Colegrave/Chris Sim/James Rudd

Investec

Tel: +44(0)20 7597 5970

 

Media Contact:

Dominic Barretto

Yellow Jersey PR Limited

Tel: +44(0) 7768 537 739

 

About Iofina

 

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives, produced water and natural gas. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, California, Montana, Oklahoma and Wyoming. The Group has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. The Group utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUUUBROOAWRRR
Date   Source Headline
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20214:35 pmRNSPrice Monitoring Extension
22nd Sep 20219:58 amRNSHolding(s) in Company
10th Sep 20214:15 pmRNSHolding(s) in Company
10th Sep 20213:25 pmRNSHolding(s) in Company
15th Jul 20217:00 amRNSH1 2021 Update
18th Jun 20214:36 pmRNSPrice Monitoring Extension
18th Jun 20213:20 pmRNSResult of AGM
27th May 20214:40 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20212:06 pmRNSSecond Price Monitoring Extn
27th May 20212:00 pmRNSPrice Monitoring Extension
27th May 202111:06 amRNSSecond Price Monitoring Extn
27th May 202111:00 amRNSPrice Monitoring Extension
27th May 20217:00 amRNSHolding(s) in Company
25th May 20217:00 amRNSAnnual Financial Report
21st May 20215:50 pmRNSNotice of Results
15th Apr 20217:00 amRNSQ1 2021 Update
1st Mar 20215:36 pmRNSDirector/PDMR Shareholding
24th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Jan 20217:00 amRNSMarket Update
22nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20204:35 pmRNSPrice Monitoring Extension
22nd Dec 20202:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20202:00 pmRNSPrice Monitoring Extension
16th Dec 202011:50 amRNSGrant of Share Options
16th Oct 20207:00 amRNSQ3 2020 Update
13th Oct 20204:40 pmRNSSecond Price Monitoring Extn
13th Oct 20204:35 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSINTERIM RESULTS
23rd Sep 20207:09 amRNSPrice Monitoring Extension
23rd Sep 20207:07 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
23rd Sep 20207:01 amRNSSecond Price Monitoring Extn
22nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20202:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20202:00 pmRNSPrice Monitoring Extension
22nd Sep 20207:00 amRNSDebt Refinancing Signed
26th Aug 20207:00 amRNSDebt Update
31st Jul 20208:00 amRNSLaunch of new website
22nd Jul 202011:06 amRNSSecond Price Monitoring Extn
22nd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSCorporate Update
30th Jun 20202:36 pmRNSDebt Update
30th Jun 202011:52 amRNSResult of AGM
26th Jun 20201:26 pmRNSChange of venue for AGM on 30 June 2020
26th Jun 20207:00 amRNSIO#8 and Debt Update
27th May 20207:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.